GREENWICH, Conn. / Apr 12, 2025 / Business Wire / Soleus Capital Management, L.P. (“Soleus Capital”), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ: THTX) (the “Company”), today sent a letter to the Board of Directors of the Company.

In its letter, Soleus Capital described its belief that an acquisition of the Company is in the best interest of the Company’s shareholders and urged the Board to pursue an acquisition offer announced earlier today by Future Pak, LLC at a price of at least $3.51 per share, representing a premium of at least 163% to the closing price of the Company on April 10^th.

The letter also described Soleus Capital’s concern that management of the Company and the Board had repeatedly ignored and/or been unresponsive to potential interested parties who have reached out to Company management for the purpose of entering into acquisition talks, which is inconsistent with management’s and the Board’s obligations to shareholders.

Soleus stated that, given the significant premium and all-cash nature of the Future Pak offer, significantly more value would accrue to shareholders by accepting the offer rather than continuing as a standalone company or in any potential alternative combination which prioritizes management job preservation over shareholder value.

The full letter is available via this link: Letter to The Board

About Soleus Capital

Soleus Capital is a healthcare investment firm located in Greenwich, CT which manages hedge, private equity and credit funds primarily focused on the innovative areas of life sciences, including biotech, medtech, diagnostics, and genomics.

Disclaimer

The views expressed in this letter represent the opinions of Soleus Capital and are based on publicly available information with respect to the Company. Soleus Capital reserves the right to change any of its opinions expressed herein at any time as it deems appropriate and disclaims any obligation to notify the market or any other party of such change. Soleus Capital disclaims any obligation to update the information or opinions contained in the linked letter.

This letter is provided merely as information and is not intended to be, nor should it be construed as investment advice, or as an offer to sell or a solicitation of an offer to buy any security. This letter does not recommend the purchase or sale of any security. Soleus Capital currently beneficially owns shares of the Company. Soleus Capital is in the business of trading – buying and selling– securities and intends to continue trading in the securities of the Company. You should assume Soleus Capital will from time to time sell all or a portion of its holdings of the Company in open market transactions or otherwise, buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares.